NASA's InSight Survived the Trip to Mars ー Now Comes the Wait for Results
*By Conor White*
The Curiosity rover is no longer alone on Mars.
NASA's InSight lander successfully touched down on the Red Planet Monday afternoon, but spectators will have months to wait before any results arrive.
"It's a 26-month mission," said Sarah Lewin, an associate editor at Space.com said. The first results from InSight's experiments are expected sometime in the spring.
InSight marks NASA's first mission to Mars since Curiosity began its journey in 2011. The launch was originally scheduled for 2016 before officials discovered a leak in the rocket's vacuum chamber. As a result, InSight missed its launch window. The delay and necessary repairs added almost $154 million to the mission's price tag, bringing it to a total cost of $814 million.
And even those years of planning didn't guarantee a success.
"Mars missions have like a 40 percent success rate across the world," Lewin said. "NASA is a little bit higher, so there was a definite chance it wouldn't work."
Now that it has safely landed, the probe will be responsible for drilling into Mars ー largely to determine the planet's composition. The robot will also monitor the planet for "Marsquakes."
"We've put a lot of things on Mars that are either orbiters, which are looking down on it, or rovers like Curiosity exploring the surface, but we really don't know what's going on inside," Lewin said.
On Monday, football fans were stunned when Buffalo Bills safety Damar Hamlin collapsed and suffered cardiac arrest. Cheddar News explains the condition and the steps to take if you witness an incident.
What's being called an unprecedented breakthrough in cancer treatment recently completed a small trial at New York City's Memorial Sloan Kettering in 14 rectal cancer patients. The experimental trial with the drug dostarlimab resulted in 100 percent remission in all candidates, precluding the need for chemotherapy or surgery. Cheddar News anchor Hena Doba dives into this hopeful story.
Join Cheddar News as we break down the top headlines this morning including updates on the Jan. 6 hears, the PGA suspension of 17 of the world's best golfers, and NASA's plans to study UFOs.
Rick Pauls, President & CEO OF DiaMedica Therapeutics, joins Cheddar Innovates to discuss a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients.
John Bencich, CEO of Achieve Life Sciences, joins Cheddar Innovates to discuss a new plant-based compound that's being used to fight nicotine addiction.
On this episode of Cheddar Innovates: CEO of Achieve Life Sciences discusses a new plant-based compound that's being used to fight nicotine addiction; President & CEO OF DiaMedica Therapeutics explains a new ischemic stroke treatment option that expands the window for effective therapy for stroke patients; Cheddar gets a look at Curiosity Stream's 'Asteroid Rush.'
